Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
On May12, 2017, Recro Pharma, Inc. (the Company) held its
2017 Annual Meeting of Shareholders (the Annual Meeting).
The following is a brief description of the final voting results
for each of the proposals submitted to a vote of the shareholders
at the Annual Meeting.
| (a) |
Proposal 1 Election of Class III Directors. Each of Alfred Altomari, William L. Ashton and Dr.Michael Berelowitz were elected to the Board of Directors as Class III directors to serve until the Companys 2020 annual meeting of shareholders, as follows: |
|
Name |
VotesFor | VotesWithheld | BrokerNon-Votes | |||||||
| Alfred Altomari | 13,157,405 | 508,828 | 2,818,253 | |||||||
| William L. Ashton | 13,628,626 | 37,607 | 2,818,253 | |||||||
| Dr.Michael Berelowitz | 13,628,426 | 37,807 | 2,818,253 |
| (b) |
Proposal 2 Ratification of Independent Registered Public Accountants. The appointment of KPMG LLP as the Companys independent registered public accounting firm for the 2017 fiscal year was ratified, as follows: |
|
VotesFor |
VotesAgainst |
Abstentions |
BrokerNon-Votes |
|||
| 16,364,163 | 117,164 | 3,159 |
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients. Recro Pharma, Inc. (NASDAQ:REPH) Recent Trading Information
Recro Pharma, Inc. (NASDAQ:REPH) closed its last trading session up +0.04 at 8.39 with 384,440 shares trading hands.
